Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2021 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the...
December 11, 2020 07:05 ET | Source: Myriad Genetics, Inc.

New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations

SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS), Myriad Genetics (NASDAQ: MYGN), a global leader in...
November 17, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression

SALT LAKE CITY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- A new nationwide poll, the GeneSight® Mental Health Monitor, shows that nearly two-thirds (61%) of Americans age 65 or older who have concerns about...
November 16, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad...
November 11, 2020 07:05 ET | Source: Myriad Genetics, Inc.

New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis

SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- At the annual meeting of the American College of Rheumatology (ACR), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and...
November 09, 2020 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter

Highlights: Revenue of $145.2 million up 56% sequentially in quarter ended Sept. 30, 2020GAAP operating income increased $28.7 million sequentially; non-GAAP operating income increased $30.2...
November 04, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings...
October 19, 2020 11:13 ET | Source: Myriad Genetics, Inc.

Gemeinsamer Bundesausschuss (G-BA) fasst Beschluss zur Erstattung der Kosten des Brustkrebs-Prognosetests EndoPredict® durch die gesetzlichen Krankenkassen

NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN SALT LAKE CITY, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:...
October 16, 2020 09:05 ET | Source: Myriad Genetics, Inc.

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SALT LAKE CITY, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader...
October 15, 2020 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests

SALT LAKE CITY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has filed...